Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).Materials and Methods We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.Results Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).Conclusion In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.
Abstract
Purpose This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).Materials and Methods We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.Results Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).Conclusion In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.
참고문헌 (34)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2022", Cancer Research and Treatment, 54(2), pp.345~351 (2022), 대한암학회[DOI]
- Lim MC, "Inci-dence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015", J Gynecol Oncol, 30, pp.e38~ (2019)
- Lheureux S, "Epithelial ovarian cancer", Lancet, 393, pp.1240~1253 (2019)
- Kim S, "Tumor evolution and chemoresistance in ovarian cancer", NPJ Precis Oncol, 2, pp.20~ (2018)
- "Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1.2022" (2022)[URL]
- Colombo N, "ESMO-ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger", Ann Oncol, 30, pp.672~705 (2019)
- Ledermann J, "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer", N Engl J Med, 366, pp.1382~1392 (2012)
- Mirza MR, "Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer", N Engl J Med, 375, pp.2154~2164 (2016)
- Pujade-Lauraine E, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1", 2 mutation(SOLO2, Lancet Oncol, pp.2017, 18[DOI]
- Poveda A, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1", 2 mutation(SOLO2, Lancet Oncol, pp.2021, 22[DOI]
- Kuchenbaecker KB, "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers", JAMA, 317, pp.2402~2416 (2017)
- Tan DS, ""BRCAness"syndrome in ovarian cancer : a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations", J Clin Oncol, 26, pp.5530~5536 (2008)
- 김세익, "Germline and Somatic BRCA1", 2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea, 2020, pp.52(4), 1229~1241[DOI]
- Aghajanian C, "OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer", J Clin Oncol, 30, pp.2039~2045 (2012)
- Coleman RL, "Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer(NRG Oncology", Gynecologic Oncology Group study GOG-0213) : a multicentre, open-label, randomised, phase 3 trial, 2017, pp.18, 779~791
- Harter P, "Randomized trial of cytoreductive surgery for relapsed ovarian cancer", N Engl J Med, 385, pp.2123~2131 (2021)
- Shi T, "Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer(SOC-1) : a multicentre, open-label, randomised, phase 3 trial", Lancet Oncol, 22, pp.439~449 (2021)
- Kim SI, "Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer", ESMO Open, 6, pp.100149~ (2021)
- Harter P, "Prospective validation study of a predictive score for operability of recurrent ovarian cancer : the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO", Int J Gynecol Cancer, 21, pp.289~295 (2011)
- Coleman RL, "Secondary surgical cytoreduction for recurrent ovarian cancer", N Engl J Med, 381, pp.1929~1939 (2019)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- 서동훈, "Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement", Journal of Gynecologic Oncology, 29(4), pp.1~18 (2018), 대한부인종양학회[DOI]
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Hyman DM, "Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer", Cancer, 118, pp.3703~3709 (2012)
- Alsop K, "BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer : a report from the Australian Ovarian Cancer Study Group", J Clin Oncol, 30, pp.2654~2663 (2012)
- Tewari KS, "Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer", J Clin Oncol, 37, pp.2317~2328 (2019)
- Lorusso D, "Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer : a large, retrospective, multicenter case-control study", Gynecol Oncol, 159, pp.95~100 (2020)
- Vencken P, "Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients", Ann Oncol, 22, pp.1346~1352 (2011)
- Fuso Nerini I, "Combination therapy in cancer : effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics", Chin J Cancer, 35, pp.61~ (2016)
- Baek MH, "Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer : a meta-analysis", J Clin Oncol, 40, pp.1659~1670 (2022)
- 이유영, "Major clinical research advances in gynecologic cancer in 2020", Journal of Gynecologic Oncology, 32(4), pp.1~18 (2021), 대한부인종양학회[DOI]
- Batlle E, "Cancer stem cells revisited", Nat Med, 23, pp.1124~1134 (2017)
- Marchetti C, "Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study", Gynecol Oncol, 155, pp.400~405 (2019)
- Ha HI, "Clinical outcomes of BRCA1", 2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer, 2022, pp.164, 415~420